Mandatory items		Optional items
Methods
Study design	Parallel group RCT i.e. people randomized to treatment Within-person RCT i.e. eyes randomized to treatment Cluster RCT i.e. communities randomized to treatment Cross-over RCT Other, specify	Number of study arms Method of randomization Exclusions after randomization Losses to follow up Number randomized/analyzed Method of masking How were missing data handled? e.g. available case analysis, imputation methods Reported power calculation (Y/N), if yes, sample size and power Unusual study design/issues
Eyes	One eye included in study, specify how eye selected Two eyes included in study, both eyes received same treatment, briefly specify how analyzed (best/worst/average/both and adjusted for within person correlation/both and not adjusted for within person correlation) and specify if mixture of one eye and two eyes Two eyes included in study, eyes received different treatments, specify if correct pair-matched analysis done
Unit of randomization/unit of analysis
Participants
Country		Setting Ethnic group Method of recruitment
Total number of participants	This information should be collected for total study population recruited into the study. If these data are reported for the people who were followed up only, please indicate.
Number (%) of men and women		Number (%) of men and women
Average age and age range		Average age and age range
Inclusion criteria
Exclusion criteria
Interventions
Intervention (n=)	Number of people randomized to this group Intervention name Comparator name Specify whether phacoemulsification, or other intervention, performed at same time as intervention	iStent or iStent inject surgical parameters, e. g. degrees of meshwork ablated, electrosurgical power Comparator parameters, e.g. dosage of drugs
Comparator (n=)
See MECIR 65 and 70
Outcomes
Primary and secondary outcomes as defined in study reports	Proportion of participants who are dropfree at 2 years follow-up Mean change in number of IOP-lowering drops taken per day from baseline to 2 years follow-up Mean change in IOP from baseline to 2 years follow-up Health-related quality of life measures at 2 years follow-up Intraoperative complications Adverse events reported (Y/N)	Planned/actual length of follow-up
See MECIR R70
Notes
Date conducted	Specify dates of recruitment of participants mm/yr to mm/yr	Full study name: (if applicable) Date of publication Reported subgroup analyses (Y/N) Were trial investigators contacted?
Sources of funding
Declaration of interest
See MECIR 69